Anti-CD20 therapy in systemic lupus erythematosus: A step closer to the clinic

This publication has 37 references indexed in Scilit:

• Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin’s Lymphoma
  Clinical Cancer Research, 2004
• The role of the BAFF/APRIL system in B cell homeostasis and lymphoid cancers
  Current Opinion in Pharmacology, 2004
• Sequential Therapies for Proliferative Lupus Nephritis
  New England Journal of Medicine, 2004
• Treatment of severe proliferative lupus nephritis: the current state
  Annals of the Rheumatic Diseases, 2003
• Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti‐CD154: A randomized, double‐blind, placebo‐controlled trial
  Arthritis & Rheumatism, 2002
• Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity
  Nature Immunology, 2001
• Mice carrying a CD20 gene disruption
  Immunogenetics, 1998
• CD20: a regulator of cell-cycle progression of B lymphocytes
  Immunology Today, 1994
• Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
  Blood, 1994
• Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas
  Blood, 1987